These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 15750033)

  • 1. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
    Lin G; Credito K; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
    Shibl AM; Ishag AH; Durgham SM
    APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of dalbavancin against staphylococci isolated in Istanbul, Turkey.
    Aktas G; Derbentli S
    Chemotherapy; 2010; 56(6):444-7. PubMed ID: 21088395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of spontaneous resistance to glycopeptide antibiotics in staphylococcal populations.
    Biavasco F; Montanari MP; Facinelli B; Varaldo PE
    J Chemother; 1989 Jul; 1(4 Suppl):389-90. PubMed ID: 16312453
    [No Abstract]   [Full Text] [Related]  

  • 19. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of susceptibility of methicillin resistant Staphylococcus aureus strains to vancomycin].
    Młynarczyk G; Młynarczyk A; Meisel-Mikołajczyk F
    Med Dosw Mikrobiol; 1995; 47(3-4):133-9. PubMed ID: 8833924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.